Adherence to inhaled corticosteroids in patients with asthma prior to and during the COVID-19 pandemic

Adherence to inhaled corticosteroids in patients with asthma prior to and during the COVID-19 pandemic

The electronic prescription refill rate (EPRR) of 183 consecutive patients was determined over a 19-month retrospective study period, divided into 7 months PRE (Sep-19 to Mar-20) and 12 months POST pandemic (Apr-20 to Mar-21), in order to compare adherence to inhaled corticosteroids (ICS) in patient...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 13; no. 1; p. 13086
Main Authors: Rodríguez, Isabel, López-Caro, Juan Carlos, Gonzalez-Carranza, Silvia, Cerrato, Maria Elena, De Prado, Maria Mar, Gomez-Molleda, Francisca, Pinel, Margarita, Saiz, Maria Teresa, Fuentes, Carmen, Barreiro, Esther, Santibáñez, Miguel
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 11-08-2023
Nature Publishing Group
Nature Portfolio
Subjects:
692/699
692/700
Administration, Inhalation
Adrenal Cortex Hormones - therapeutic use
Anti-Asthmatic Agents - therapeutic use
Asthma
Asthma - drug therapy
Asthma - epidemiology
Corticoids
Corticosteroids
COVID-19
COVID-19 - epidemiology
Drug Prescriptions
Humanities and Social Sciences
Humans
Inhalers
Medication Adherence
multidisciplinary
Pandemics
Retrospective Studies
Science
Science (multidisciplinary)
Steroids
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The electronic prescription refill rate (EPRR) of 183 consecutive patients was determined over a 19-month retrospective study period, divided into 7 months PRE (Sep-19 to Mar-20) and 12 months POST pandemic (Apr-20 to Mar-21), in order to compare adherence to inhaled corticosteroids (ICS) in patients with asthma prior to and during the COVID-19 pandemic. Before the pandemic (PRE), an average of 0.58 inhalers/month were refill from the pharmacy; [SD 0.33], very similar to the 0.59 inhalers/month; [SD 0.34] retrieved during the 12 subsequent months since the pandemic (POST) (p = 0.768). EPRR showed no differences (p = 0.784). When EPRR was dichotomous or ordinal categorised no differences were found either (p = 0.851 and 0.928), even when McNemar's test was used (p = 0.949), with prevalences of nonadherence (EPRR < 80%) of 57 and 58% respectively. Our results do not support increased adherence to inhaler treatment in terms of EPRR, comparing before and since COVID-19 pandemic. Compliance with prescription remains suboptimal.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-40213-6